Medium

Step 1: The overall sentiment of the management's discussion appears to be a mix of challenges due to COVID-19 impact and proactive measures taken to mitigate risks. While there are mentions of adverse impacts such as decreased pharmaceutical distribution volumes and increased expenses related to COVID-19 response, there are also positive notes on revenue growth in certain segments and partnerships to support vaccine distribution. This mix of challenges and efforts to adapt suggests a cautious outlook.

Step 2: 
- Working Capital to Total Assets (X1) is negative (-0.0588), indicating potential liquidity challenges.
- Retained Earnings to Total Assets (X2) at 0.1972 may suggest relatively solid retained earnings.
- EBIT to Total Assets (X3) at 0.0783 indicates a moderate return generated on the total assets.
- Total Revenue to Total Assets (X5) at 4.4402 shows a high proportion of revenue generated compared to total assets.

Step 3: The negative working capital to total assets ratio (X1) implies potential liquidity issues. This, combined with the challenges mentioned in the management discussion related to COVID-19 impact on pharmaceutical distribution volumes and increased expenses, indicates a challenging quarter. However, the relatively strong revenue to total assets ratio (X5) could signal resilience in generating revenue despite the difficulties.

Step 4: Considering the mix of challenges highlighted in the management's discussion, along with the negative working capital ratio and the moderate return on assets, the company appears to have a medium risk of bankruptcy. While there are revenue generation strengths, liquidity challenges and potential impacts from COVID-19 pose significant risks that need to be managed effectively.